Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 101

Similar articles for PubMed (Select 21970596)

1.

Pharmacogenetic testing affects choice of therapy among women considering tamoxifen treatment.

Lorizio W, Rugo H, Beattie MS, Tchu S, Melese T, Melisko M, Wu AH, Lawrence HJ, Nikoloff M, Ziv E.

Genome Med. 2011 Oct 4;3(10):64. doi: 10.1186/gm280.

2.

Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen.

Schroth W, Goetz MP, Hamann U, Fasching PA, Schmidt M, Winter S, Fritz P, Simon W, Suman VJ, Ames MM, Safgren SL, Kuffel MJ, Ulmer HU, Boländer J, Strick R, Beckmann MW, Koelbl H, Weinshilboum RM, Ingle JN, Eichelbaum M, Schwab M, Brauch H.

JAMA. 2009 Oct 7;302(13):1429-36. doi: 10.1001/jama.2009.1420.

3.

The clinical effectiveness and cost-effectiveness of genotyping for CYP2D6 for the management of women with breast cancer treated with tamoxifen: a systematic review.

Fleeman N, Martin Saborido C, Payne K, Boland A, Dickson R, Dundar Y, Fernández Santander A, Howell S, Newman W, Oyee J, Walley T.

Health Technol Assess. 2011 Sep;15(33):1-102. doi: 10.3310/hta15330. Review.

4.

Association between CYP2D6 genotype and tamoxifen-induced hot flashes in a prospective cohort.

Henry NL, Rae JM, Li L, Azzouz F, Skaar TC, Desta Z, Sikora MJ, Philips S, Nguyen AT, Storniolo AM, Hayes DF, Flockhart DA, Stearns V; Consortium on Breast Cancer Pharmacogenomics Investigators.

Breast Cancer Res Treat. 2009 Oct;117(3):571-5. doi: 10.1007/s10549-009-0309-1. Epub 2009 Jan 20.

5.

CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial.

Regan MM, Leyland-Jones B, Bouzyk M, Pagani O, Tang W, Kammler R, Dell'orto P, Biasi MO, Thürlimann B, Lyng MB, Ditzel HJ, Neven P, Debled M, Maibach R, Price KN, Gelber RD, Coates AS, Goldhirsch A, Rae JM, Viale G; Breast International Group (BIG) 1-98 Collaborative Group.

J Natl Cancer Inst. 2012 Mar 21;104(6):441-51. doi: 10.1093/jnci/djs125. Epub 2012 Mar 6.

6.

Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II.

Zhou SF.

Clin Pharmacokinet. 2009;48(12):761-804. doi: 10.2165/11318070-000000000-00000.

PMID:
19902987
7.

The AmpliChip CYP450 genotyping test: Integrating a new clinical tool.

de Leon J, Susce MT, Murray-Carmichael E.

Mol Diagn Ther. 2006;10(3):135-51. Review.

PMID:
16771600
8.

The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen.

Goetz MP, Knox SK, Suman VJ, Rae JM, Safgren SL, Ames MM, Visscher DW, Reynolds C, Couch FJ, Lingle WL, Weinshilboum RM, Fritcher EG, Nibbe AM, Desta Z, Nguyen A, Flockhart DA, Perez EA, Ingle JN.

Breast Cancer Res Treat. 2007 Jan;101(1):113-21. Epub 2006 Nov 18.

PMID:
17115111
9.

Does pharmacogenetic testing for CYP450 2D6 and 2C19 among patients with diagnoses within the schizophrenic spectrum reduce treatment costs?

Herbild L, Andersen SE, Werge T, Rasmussen HB, Jürgens G.

Basic Clin Pharmacol Toxicol. 2013 Oct;113(4):266-72. doi: 10.1111/bcpt.12093. Epub 2013 Jul 6.

PMID:
23731498
10.

Influence of CYP2D6 polymorphisms on serum levels of tamoxifen metabolites in Spanish women with breast cancer.

Zafra-Ceres M, de Haro T, Farez-Vidal E, Blancas I, Bandres F, de Dueñas EM, Ochoa-Aranda E, Gomez-Capilla JA, Gomez-Llorente C.

Int J Med Sci. 2013 May 27;10(7):932-7. doi: 10.7150/ijms.5708. Print 2013.

11.

No association found between CYP2D6 genotype and early breast cancer events in tamoxifen-treated patients.

Markkula A, Hjertberg M, Rose C, Ingvar C, Jernström H.

Acta Oncol. 2014 Feb;53(2):195-200. doi: 10.3109/0284186X.2013.840739. Epub 2013 Oct 14.

PMID:
24125101
12.

Patients' understanding of how genotype variation affects benefits of tamoxifen therapy for breast cancer.

Brewer NT, Defrank JT, Chiu WK, Ibrahim JG, Walko CM, Rubin P, Olajide OA, Moore SG, Raab RE, Carrizosa DR, Corso SW, Schwartz G, Peppercorn JM, McLeod HL, Carey LA, Irvin WJ Jr.

Public Health Genomics. 2014;17(1):43-7. doi: 10.1159/000356565. Epub 2014 Jan 22.

13.

CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients.

Rae JM, Drury S, Hayes DF, Stearns V, Thibert JN, Haynes BP, Salter J, Sestak I, Cuzick J, Dowsett M; ATAC trialists.

J Natl Cancer Inst. 2012 Mar 21;104(6):452-60. doi: 10.1093/jnci/djs126. Epub 2012 Mar 6. Erratum in: J Natl Cancer Inst. 2012 Nov 21;104(22):1772.

14.

Personalized medicine in breast cancer: tamoxifen, endoxifen, and CYP2D6 in clinical practice.

Ruddy KJ, Desantis SD, Gelman RS, Wu AH, Punglia RS, Mayer EL, Tolaney SM, Winer EP, Partridge AH, Burstein HJ.

Breast Cancer Res Treat. 2013 Oct;141(3):421-7. doi: 10.1007/s10549-013-2700-1. Epub 2013 Sep 24.

PMID:
24062210
15.

Effect of CYP2D6 polymorphisms on breast cancer recurrence.

Morrow PK, Serna R, Broglio K, Pusztai L, Nikoloff DM, Hillman GR, Fontecha M, Li R, Michaud L, Hortobagyi G, Gonzalez-Angulo AM.

Cancer. 2012 Mar 1;118(5):1221-7. doi: 10.1002/cncr.26407. Epub 2011 Aug 5.

16.

Side effects associated with ultrarapid cytochrome P450 2D6 genotype among women with early stage breast cancer treated with tamoxifen.

Rolla R, Vidali M, Meola S, Pollarolo P, Fanello MR, Nicolotti C, Saggia C, Forti L, Agostino FD, Rossi V, Borra G, Stratica F, Alabiso O, Bellomo G.

Clin Lab. 2012;58(11-12):1211-8.

PMID:
23289191
17.

CYP3A4 and seasonal variation in vitamin D status in addition to CYP2D6 contribute to therapeutic endoxifen level during tamoxifen therapy.

Teft WA, Gong IY, Dingle B, Potvin K, Younus J, Vandenberg TA, Brackstone M, Perera FE, Choi YH, Zou G, Legan RM, Tirona RG, Kim RB.

Breast Cancer Res Treat. 2013 May;139(1):95-105. doi: 10.1007/s10549-013-2511-4. Epub 2013 Apr 12. Erratum in: Breast Cancer Res Treat. 2013 Nov;142(1):225.

PMID:
23580071
18.

Endoxifen levels and its association with CYP2D6 genotype and phenotype: evaluation of a southern Brazilian population under tamoxifen pharmacotherapy.

Antunes MV, Linden R, Santos TV, Wallemacq P, Haufroid V, Classen JF, Andreolla H, Costa N, Fontanive TO, Rosa DD.

Ther Drug Monit. 2012 Aug;34(4):422-31. doi: 10.1097/FTD.0b013e318260b46e.

PMID:
22777153
19.

Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysis.

Punglia RS, Burstein HJ, Winer EP, Weeks JC.

J Natl Cancer Inst. 2008 May 7;100(9):642-8. doi: 10.1093/jnci/djn100. Epub 2008 Apr 29.

20.

Clinical guidelines for psychiatrists for the use of pharmacogenetic testing for CYP450 2D6 and CYP450 2C19.

de Leon J, Armstrong SC, Cozza KL.

Psychosomatics. 2006 Jan-Feb;47(1):75-85. Review.

PMID:
16384813
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk